BACK has completed the acquisition of Theralink Technologies, Inc.’s assets on May 7, 2024. The agreement was settled due to Theralink’s default on outstanding debt and involved the transfer of certain assets to BACK. In connection with this settlement, IMAC Merger Sub, Inc., Theralink, and BACK terminated a previous Agreement and Plan of Merger on May 6, 2024. This termination eliminates the need for a merger and allows for a more streamlined process going forward.
IMAC Holdings, Inc.’s CEO Jeff Ervin highlighted the benefits of the settlement for both companies. Theralink’s advancements in breast cancer diagnostics can now move forward under BACK’s ownership. The company is focused on stabilizing operations, transitioning key employees, and capitalizing on the expertise in proteomic analysis and precision medicine within the team.
IMAC Holdings is a clinical research and commercialization company specializing in Innovative Medical Advancements and Care in oncology, neurological, and orthopedic specialties. For more information about IMAC Holdings, visit www.imacholdings.com. Investors can contact jeff@imacholdings.com for further information regarding this acquisition announcement from IMAC Holdings.
